Purpose: Angiogenesis is critical for tumor growth and a promising therapeutic target. This review will summarize and analyze data from clinical trials of anti-angiogenic agents in the treatment of breast cancer (BC).
Design: A systematic search of PubMed and conference databases was performed to identify reports of randomized clinical trials investigating specific anti-angiogenic agents in the treatment of BC.
Results And Discussion: Phase III trials in advanced BC have demonstrated a reduction in the risk of disease progression (22-52%), improved response rates and net improvements in progression-free survival of 1.2 to 5.5 months, but no significant improvements in overall survival with the addition of bevacizumab to chemotherapy. Results of phase III trials in early breast cancer have been inconsistent. Bevacizumab-containing regimens have also been associated with higher overall adverse event rates compared to chemotherapy alone. Phase III trials of the tyrosine kinase inhibitor sunitinib were negative, while randomized phase II trials of sorafenib and pazopanib have improved some outcomes when combined with chemotherapy or targeted therapy compared to controls. In addition to expected vascular class safety signals, tyrosine kinase inhibitors show "off-target" side effects. Ongoing clinical trials evaluating combinatorial strategies based on biological synergies and translational studies identifying biological predictors of response will be crucial to establish meaningful clinical benefits in selected BC populations.
Conclusion: Most trials of anti-angiogenic agents in BC have reported improved response rate and progression-free survival but no increase in overall survival compared to chemotherapy alone. Optimizing the therapeutic indices of these agents is a focus of ongoing research and will be critical to their future development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ctrv.2011.12.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Perceived Discrimination and Pandemic Attitudes on Cancer Screening Behaviors Among Asian American Women: A Sequential Explanatory Mixed-Methods Study.
J Am Coll Radiol
December 2024
Vice Chair for Radiology, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts; Co-Chair, RSNA Health Equity Committee; Associate Editor, Journal of the American College of Radiology.
Purpose: The aim of this study was to assess how pandemic-related health concerns and discrimination affected cancer screenings among Asian American women (AAW).
Methods: A two-phase explanatory mixed-methods study was conducted. In phase 1, a survey was distributed among AAW eligible for lung, breast, or colorectal cancer screening to assess delays during the pandemic, concerns about contracting coronavirus disease 2019 (COVID-19), barriers to care, and experiences of discrimination.
Evaluating Body Image Disturbance and Its Influencing Factors in Breast Cancer Patients Following Unilateral Mastectomy.
Psychiatry Clin Psychopharmacol
December 2024
Department of Operating Room, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Central Hospital, Lishui, China.
Background: Patients with unilateral breast loss after single mastectomy for breast cancer may have body image disorders such as surgical lymphedema, flap ischemia, and spinal deformity, resulting in negative emotions such as depression, inferiority, and social dysfunction. This study mainly investigated and analyzed the status quo and influencing factors of body image disorder in breast cancer patients after single mastectomy.
Methods: This study is a cross-sectional study.
Optimized Synthetic Correlated Diffusion Imaging for Improving Breast Cancer Tumor Delineation.
Sensors (Basel)
December 2024
Department of Systems Design Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
Breast cancer is a significant cause of death from cancer in women globally, highlighting the need for improved diagnostic imaging to enhance patient outcomes. Accurate tumor identification is essential for diagnosis, treatment, and monitoring, emphasizing the importance of advanced imaging technologies that provide detailed views of tumor characteristics and disease. Recently, a new imaging modality named synthetic correlated diffusion imaging (CDI) has been showing promise for enhanced prostate cancer delineation when compared to existing MRI imaging modalities.
View Article and Find Full Text PDFMR Elastography Using the Gravitational Transducer.
Sensors (Basel)
December 2024
Research Department of Imaging Physics and Engineering, School of Biomedical Engineering and Imaging Sciences, King's College London, London WC2R 2LS, UK.
MR elastography is a non-invasive imaging technique that provides quantitative maps of tissue biomechanical properties, i.e., elasticity and viscosity.
View Article and Find Full Text PDFA New Heteroleptic Zn(II) Complex with Schiff Bases Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel.
Pharmaceutics
December 2024
Laboratory of Genetics and Biotechnology, Institute of Biotechnology, Federal University of Uberlândia, Patos de Minas 38700-002, MG, Brazil.
: Triple-negative breast cancer (TNBC) is the most challenging molecular subtype of breast cancer (BC) in clinical practice, associated with a worse prognosis due to limited treatment strategies and its insensitivity to conventional drugs. Zinc is an important trace element for homeostasis, and its Schiff base metal complexes have shown promise in treating advanced tumors. In this study, four new heteroleptic Zn(II) complexes (-) with Schiff bases were synthesized, characterized, and evaluated for their activity in BC cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!